EP4476202A1 — Stereoselective technologies for chiral compounds
Assigned to Wave Life Sciences Pte Ltd · Expires 2024-12-18 · 1y expired
What this patent protects
Among other things, the present disclosure provides technologies for stereoselective preparation chiral compounds. In some embodiments, prepared chiral compounds are useful for chirally controlled preparation of oligonucleotides. In some embodiments, such oligonucleotides target …
USPTO Abstract
Among other things, the present disclosure provides technologies for stereoselective preparation chiral compounds. In some embodiments, prepared chiral compounds are useful for chirally controlled preparation of oligonucleotides. In some embodiments, such oligonucleotides target transcripts associate with various conditions, disorders or diseases.
Drugs covered by this patent
- Krazati (ADAGRASIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.